Showing 5311-5320 of 8159 results for "".
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- FDA Approves Updated Label for New Dosing Regimen for Allergan's Dalvancehttps://practicaldermatology.com/news/fda-approves-updated-label-for-new-dosing-regimen-for-allergans-dalvance/2458741/The FDA has approved Allergan plc’s supplemental new drug application (sNDA) to update the label for Dalvance® (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of Dalvance for the treatment o
- Data: EpiDuo Forte Shows Benefit in Severe Inflammatory Acnehttps://practicaldermatology.com/news/data-epiduo-forte-shows-benefit-in-severe-inflammatory-acne/2458743/New data suggest that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% from Galderma, recently approved for the treatment of moderate to severe acne vulgaris, may have benefit for the topical treatment of severe inflammatory acne. Data published for the in the Dece
- New World Market for Prescription Dermatological Drugs Report Releasedhttps://practicaldermatology.com/news/new-world-market-for-prescription-dermatological-drugs-report/2458749/Research and Markets recently added the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer,Melasma and Seborrhea Treatments)&qu
- Study Highlights Risk Factors for cSCC Recurrence, Metastasis and Deathhttps://practicaldermatology.com/news/study-highlights-risk-factors-for-cscc-recurrence-metastasis-and-death/2458753/Tumor depth confers the highest risk of local recurrence and metastasis of cutaneous squamous cell carcinoma (cSCC) and tumor diameter exceeding 20 mm is associated with the highest risk for disease-specific death, a new study suggests. The findings are published online in
- Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisorhttps://practicaldermatology.com/news/psoria-shield-inc-names-dr-steven-feldman-as-scientific-advisor/2458754/Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisor Wellness Center USA, Inc.’s wholly owned subsidiary, Psoria-Shield, Inc. (PSI) named Steven Feldman, MD, PhD as Scientific Advisor. Dr. Feldman is a Professor of Dermatology, Professor of Pathology, and Professor of
- Study: With Botox 'Chemodenervation,' Dermal Fillers Last Longerhttps://practicaldermatology.com/news/study-with-botox-chemodenervation-dermal-fillers-last-longer/2458757/Experimental evidence supports a simple technique for prolonging the effects of Hyaluronic acid (HA) dermal fillers: using them together with botulinum toxin, according to a study published in the January issue of Plastic and
- Dermira Completes Patient Enrollment for Third Cimzia Phase 3 Trial in Psoriasis Programhttps://practicaldermatology.com/news/dermira-completes-patient-enrollment-for-third-cimzia-phase-3-trial-in-psoriasis-program/2458760/Dermira, Inc., completed its patient enrollment for the CIMPACT clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-s
- Dermatologist Dr. Jill Waibel Selected as Keynote Speaker for Orlando Dermhttps://practicaldermatology.com/news/dermatologist-dr-jill-waibel-selected-as-keynote-speaker-for-orlando-derm/2458759/Laser expert and dermatologist Jill S. Waibel, MD, will provide the keynote speech, "Lasers for Trauma Rehabilitation: Giving Humans the Power to Heal Themselves," at the Orlando Dermatology Aesthetic and Clinical Conference (ODAC). Dr. Waibel was recently featured in national news cove
- Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application for VB-1953 to Treat Acnehttps://practicaldermatology.com/news/vyome-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-vb-1953-to-treat-acne/2458766/The FDA accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon. “Today m